Atopic Dermatitis News

  • AAD Immune Modulation in the Spotlight at AAD 2018 Immunomodulators for inflammatory diseases and cancer will be among the hot topics at the upcoming American Academy of Dermatology meeting.
  • Regeneron CEO Says Fears Over Eylea 'Greatly Exaggerated' Fears of the demise of blockbuster eye drug Eylea (aflibercept) were "greatly exaggerated," Regeneron Pharmaceuticals Inc's chief executive said on Thursday, after the treatment and new eczema drug Dupixent (dupilumab) powered the company's fourth-quarter results.

Atopic Dermatitis Perspective


Atopic Dermatitis Journal Articles